Literature DB >> 20455002

Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.

Yosuke Watanabe1, Fumiyuki Yamasaki, Yoshinori Kajiwara, Taiichi Saito, Takeshi Nishimoto, Chandra Bartholomeusz, Naoto T Ueno, Kazuhiko Sugiyama, Kaoru Kurisu.   

Abstract

Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) is a multifunctional protein that was first identified in brain astrocytes and that has subsequently been shown to be expressed in different tissues. Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined. We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV). PEA-15 expression levels were immunohistochemically measured and categorized as no, low, or high expression. All tumors expressed PEA-15 in our study. Twenty-three (35.4%) and 42 (64.6%) tumors expressed low and high PEA-15 levels, respectively. In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels. PEA-15 expression level was inversely associated with WHO grade (P = 0.0006). Next, we evaluated prognosis and PEA-15 expression levels in 43 patients with high-grade astrocytomas based on the following parameters: age, gender, WHO grade, surgical resection extent, MIB-1 labeling index (LI), and PEA-15 expression level. Multivariable analyses revealed that high PEA-15 expression level displayed a significant correlation with longer overall survival (OS) in high-grade astrocytomas (P = 0.0024). Patients with total resection survived significantly longer (P = 0.0044) than those with lower resection extent, while patients with MIB-1 labeling index ≤25% indicated significant (P = 0.0434) correlation with OS as well. In conclusion, PEA-15 expression level was inversely associated with WHO grade and may serve as an important prognostic factor for high-grade astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455002     DOI: 10.1007/s11060-010-0201-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Knock-out of the neural death effector domain protein PEA-15 demonstrates that its expression protects astrocytes from TNFalpha-induced apoptosis.

Authors:  D Kitsberg; E Formstecher; M Fauquet; M Kubes; J Cordier; B Canton; G Pan; M Rolli; J Glowinski; H Chneiweiss
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

2.  Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a protein kinase C delta-dependent mechanism.

Authors:  François Renault-Mihara; Frédéric Beuvon; Xavier Iturrioz; Brigitte Canton; Sophie De Bouard; Nadine Léonard; Shahul Mouhamad; Ariane Sharif; Joe W Ramos; Marie-Pierre Junier; Hervé Chneiweiss
Journal:  Mol Biol Cell       Date:  2006-09-20       Impact factor: 4.138

3.  Endothelin induces a calcium-dependent phosphorylation of PEA-15 in intact astrocytes: identification of Ser104 and Ser116 phosphorylated, respectively, by protein kinase C and calcium/calmodulin kinase II in vitro.

Authors:  M Kubes; J Cordier; J Glowinski; J A Girault; H Chneiweiss
Journal:  J Neurochem       Date:  1998-09       Impact factor: 5.372

4.  Grading of astrocytomas. A simple and reproducible method.

Authors:  C Daumas-Duport; B Scheithauer; J O'Fallon; P Kelly
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

5.  High grade glioma: imaging combined with pathological grade defines management and predicts prognosis.

Authors:  Neil G Burnet; Andrew G Lynch; Sarah J Jefferies; Stephen J Price; Phil H Jones; Nagui M Antoun; John H Xuereb; Ute Pohl
Journal:  Radiother Oncol       Date:  2007-11-26       Impact factor: 6.280

6.  Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data.

Authors:  Lawrence P Petalidis; Anastasis Oulas; Magnus Backlund; Matthew T Wayland; Lu Liu; Karen Plant; Lisa Happerfield; Tom C Freeman; Panayiota Poirazi; V Peter Collins
Journal:  Mol Cancer Ther       Date:  2008-04-29       Impact factor: 6.261

7.  The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway.

Authors:  A Eckert; B C Böck; K E Tagscherer; T L Haas; K Grund; J Sykora; C Herold-Mende; V Ehemann; M Hollstein; H Chneiweiss; O D Wiestler; H Walczak; W Roth
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

8.  Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells.

Authors:  Chang Xiao; Bao Feng Yang; Neda Asadi; Francesco Beguinot; Chunhai Hao
Journal:  J Biol Chem       Date:  2002-04-25       Impact factor: 5.157

9.  Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development.

Authors:  Pietro Formisano; Giuseppe Perruolo; Silvana Libertini; Stefania Santopietro; Giancarlo Troncone; Gregory Alexander Raciti; Francesco Oriente; Giuseppe Portella; Claudia Miele; Francesco Beguinot
Journal:  Oncogene       Date:  2005-10-27       Impact factor: 9.867

10.  Overexpression of the ped/pea-15 gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action.

Authors:  Giovanni Vigliotta; Claudia Miele; Stefania Santopietro; Giuseppe Portella; Anna Perfetti; Maria Alessandra Maitan; Angela Cassese; Francesco Oriente; Alessandra Trencia; Francesca Fiory; Chiara Romano; Cecilia Tiveron; Laura Tatangelo; Giancarlo Troncone; Pietro Formisano; Francesco Beguinot
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more
  7 in total

1.  Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.

Authors:  G Renner; H Janouskova; F Noulet; V Koenig; E Guerin; S Bär; J Nuesch; F Rechenmacher; S Neubauer; H Kessler; A-F Blandin; L Choulier; N Etienne-Selloum; M Lehmann; I Lelong-Rebel; S Martin; M Dontenwill
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

2.  Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter.

Authors:  Florian Sulzmaier; John Opoku-Ansah; Joe W Ramos
Journal:  Small GTPases       Date:  2012-06-14

3.  Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling.

Authors:  Yuki Katayama; Moegi Maeda; Ken Miyaguchi; Shota Nemoto; Mahmut Yasen; Shinji Tanaka; Hiroshi Mizushima; Yutaka Fukuoka; Shigeki Arii; Hiroshi Tanaka
Journal:  Oncol Lett       Date:  2012-07-18       Impact factor: 2.967

4.  Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.

Authors:  Xinhua Xie; Hailin Tang; Yanan Kong; Minqing Wu; Xiangsheng Xiao; Lu Yang; Jie Gao; Weidong Wei; Jangsoon Lee; Chandra Bartholomeusz; Naoto T Ueno; Xiaoming Xie
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

5.  Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK.

Authors:  Peter D Mace; Yann Wallez; Michael F Egger; Małgorzata K Dobaczewska; Howard Robinson; Elena B Pasquale; Stefan J Riedl
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 6.  On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities.

Authors:  Yufeng Wei
Journal:  Pharmaceuticals (Basel)       Date:  2015-07-31

Review 7.  Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.

Authors:  Fiona H Greig; Graeme F Nixon
Journal:  Pharmacol Ther       Date:  2014-03-20       Impact factor: 12.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.